



ASX ANNOUNCEMENT

24 APRIL 2025

EMORY WINSHIP CANCER INSTITUTE JOINS CHM CDH17 PHASE 1/2 CLINICAL TRIAL

- **CHM CDH17 is the world's first CDH17-directed CAR-T cell therapy**
- **Emory Winship Cancer Institute is Georgia's National Cancer Institute designated Comprehensive Cancer Centre**
- **Of seven patients now enrolled, four have been dosed, in addition to five successful manufacturing runs**

Melbourne, Australia, 24 April 2025: Chimeric Therapeutics (ASX:CHM, "Chimeric" or the "Company"), an Australian leader in cell therapy, is pleased to announce that Emory Winship Cancer Institute (Emory) in Atlanta, Georgia is open to enrol patients in the Phase 1/2 multi-centre clinical trial for CHM CDH17 cell therapy.

The Phase 1/2 trial (NCT06055439) is a two-stage study designed to determine a recommended Phase 2 dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumours (NETs). CHM CDH17 is a 3rd generation, novel CAR-T cell therapy that targets CDH17, a cancer biomarker associated with poor prognosis and metastases in the most common gastrointestinal tumours.

This site will be led by Associate Professor Daniel Halperin MD, who serves on the Board of Scientific Advisors of the NET Research Foundation, the Scientific Advisory Committee of the Healing NET Foundation and the Board of Directors and Symposium Committee of the North American Neuroendocrine Tumor Society. As a clinical investigator, Dr Halperin is dedicated to providing world-class clinical care and developing novel therapies for patients with NETs.

"With the successful launch of our fourth and final clinical trial site in the USA; we've reached a significant milestone in our development program. This momentum reflects our unwavering commitment to advancing cell therapy and positions us to deliver meaningful value to both patients and shareholders," said Dr Rebecca McQualter, Chimeric Therapeutics' Chief Executive Officer.

The Phase 1 portion of this study is expected to enrol up to 15 patients and lead to dose selection and expansion with indication-specific Phase 2 cohorts.



ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in 2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CLTX is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated. From the CORE-NK platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

Contact

Investors

Dr Rebecca McQualter

Chief Executive Officer

Chimeric Therapeutics

E: investors@chimerictherapeutics.com

W: www.chimerictherapeutics.com



Media

Matthew Wright

NWR Communications

T: +61 451 896 420

E: matt@nwrcommunications.com.au